Literature DB >> 19332744

The drug-drug interaction between proton pump inhibitors and clopidogrel.

Wei C Lau1, Paul A Gurbel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19332744      PMCID： PMC2659824          DOI： 10.1503/cmaj.090251

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  12 in total

1.  The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Authors:  K A Kim; P W Park; S J Hong; J-Y Park
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

2.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

3.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.

Authors:  David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani
Journal:  CMAJ       Date:  2009-01-28       Impact factor: 8.262

4.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

Authors:  Xue-Qing Li; Tommy B Andersson; Marie Ahlström; Lars Weidolf
Journal:  Drug Metab Dispos       Date:  2004-08       Impact factor: 3.922

5.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

Authors:  Martine Gilard; Bertrand Arnaud; Jean-Christophe Cornily; Grégoire Le Gal; Karine Lacut; Geneviève Le Calvez; Jacques Mansourati; Dominique Mottier; Jean-François Abgrall; Jacques Boschat
Journal:  J Am Coll Cardiol       Date:  2008-01-22       Impact factor: 24.094

6.  The influence of St John's Wort on CYP2C19 activity with respect to genotype.

Authors:  Lian-Sheng Wang; Bing Zhu; A M Abd El-Aty; Gan Zhou; Zhi Li; Jun Wu; Guo-Lin Chen; Jie Liu; Zhi Rong Tang; Wang An; Qing Li; Dan Wang; Hong-Hao Zhou
Journal:  J Clin Pharmacol       Date:  2004-06       Impact factor: 3.126

7.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

8.  Genetic determinants of response to clopidogrel and cardiovascular events.

Authors:  Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.

Authors:  Wei C Lau; Lucy A Waskell; Paul B Watkins; Charlene J Neer; Kevin Horowitz; Amy S Hopp; Alan R Tait; David G M Carville; Kirk E Guyer; Eric R Bates
Journal:  Circulation       Date:  2003-01-07       Impact factor: 29.690

10.  Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Authors:  N A Farid; C D Payne; D S Small; K J Winters; C S Ernest; J T Brandt; C Darstein; J A Jakubowski; D E Salazar
Journal:  Clin Pharmacol Ther       Date:  2007-03-14       Impact factor: 6.875
View more
  10 in total

1.  Clinical importance of aspirin and clopidogrel resistance.

Authors:  Gergely Feher; Andrea Feher; Gabriella Pusch; Katalin Koltai; Antal Tibold; Beata Gasztonyi; Elod Papp; Laszlo Szapary; Gabor Kesmarky; Kalman Toth
Journal:  World J Cardiol       Date:  2010-07-26

2.  A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.

Authors:  Hui Chen; Xiao-Ying Wu; Hong-Xia Wu; Huan Wang
Journal:  Chin J Integr Med       Date:  2014-11-27       Impact factor: 1.978

3.  The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel.

Authors:  Alf-Aage R Pettersen; Harald Arnesen; Trine B Opstad; Ingebjorg Seljeflot
Journal:  Thromb J       Date:  2011-03-22

4.  Patterns and characteristics of polypharmacy among elderly residents in Danish nursing homes.

Authors:  Jacob Astorp; Mimoza Gjela; Pernille Jensen; Rasmus D Bak; Parisa Gazerani
Journal:  Future Sci OA       Date:  2020-05-29

5.  In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong.

Authors:  Hui Chen; Ya Zhang; Xiaoying Wu; Candong Li; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-16       Impact factor: 2.629

6.  Association of KDR rs1870377 genotype with clopidogrel resistance in patients with post percutaneous coronary intervention.

Authors:  Wajdy Al Awaida; Ali A Ahmed; Asia Ali Hamza; Khalid I Amber; Hamzeh J Al-Ameer; Yazun Jarrar; Ghizal Fatima; Ahmed O Maslat; Yulia Gushchina; Omar Al Bawareed; Najah R Hadi
Journal:  Heliyon       Date:  2021-02-16

7.  P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?

Authors:  Adriana Dana Oprea; Wanda M Popescu
Journal:  Cardiol Res Pract       Date:  2013-02-19       Impact factor: 1.866

8.  Drug-drug interactions and their predictors: Results from Indian elderly inpatients.

Authors:  Mandavi Kashyap; Sanjay D'Cruz; Atul Sachdev; Pramil Tiwari
Journal:  Pharm Pract (Granada)       Date:  2013-12-20

Review 9.  The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.

Authors:  Anne Tuskey; David Peura
Journal:  Arthritis Res Ther       Date:  2013-07-24       Impact factor: 5.156

10.  Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.

Authors:  Takashi Kawai; Kazunori Oda; Nobuo Funao; Akira Nishimura; Yasushi Matsumoto; Yuji Mizokami; Kiyoshi Ashida; Kentaro Sugano
Journal:  Gut       Date:  2017-12-01       Impact factor: 23.059
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.